# Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Canonical URL: https://biopharmsignal.com/news/MDNA/medicenna-and-fondazione-melanoma-onlus-announce-first-patient-dosed-in-the-neo-cyt-study-of-mdna11-in-neoadjuvant-melanoma
Ticker: MDNA
Company: Medicenna Therapeutics Corp.
Source: Medicenna Therapeutics Corp.
Published: 2026-05-12 11:00 EST
Original Source URL: https://ir.medicenna.com
## Summary

NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2 ABILITY-1 study  NEO-CYT is a Phase 1b randomized, multi-centre trial sponsored by Fondazione

## Article Body
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2 ABILITY-1 study  NEO-CYT is a Phase 1b randomized, multi-centre trial sponsored by Fondazione
## Recent Company News
- 2026-06-03 11:00 EST — [Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026](https://biopharmsignal.com/news/MDNA/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026) — Source: Medicenna Therapeutics Corp.
- 2026-05-28 13:10 EST — [Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs](https://biopharmsignal.com/news/MDNA/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs) — Source: Medicenna Therapeutics Corp.
- 2026-05-22 11:00 EST — [Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet) — Source: Medicenna Therapeutics Corp.
- 2026-05-19 11:00 EST — [Medicenna Announces the Finalization of the Terms of its Public Offering of Securities](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-finalization-of-the-terms-of-its-public-offering-of-securities) — Source: Medicenna Therapeutics Corp.
- 2026-05-13 20:01 EST — [Medicenna Announces the Launch of a Marketed Public Offering of Securities](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-launch-of-a-marketed-public-offering-of-securities) — Source: Medicenna Therapeutics Corp.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)